In Cleveland Clinic Foundation, Cleveland Heartlab, Inc. v. True Health Diagnostics LLC, (Cleveland Clinic II)[1], a unanimous panel of the Federal Circuit provided yet another guidepost illustrating what is not...more
4/5/2019
/ Abstract Ideas ,
Appeals ,
Method Claims ,
New Guidance ,
Patent Infringement ,
Patent Invalidity ,
Patent Litigation ,
Patent-Eligible Subject Matter ,
Patents ,
Pharmaceutical Patents ,
Product of Nature Doctrine ,
Reaffirmation ,
Section 101 ,
USPTO
The Federal Circuit’s recent decision in Kaneka Corp. v. Xiamen Kingdomway Group Co. (Fed. Cir. 2015) serves as a reminder that courts may implicitly read an order into a patent’s method claim steps, even if the applicant did...more
The U.S. Supreme Court’s recent decision in Kimble et al. v. Marvel Entertainment, LLC, rejuvenates a 50-year old rule addressing patent royalties, bringing it to the forefront of patent and licensing practice. On June 22,...more
6/24/2015
/ Brulotte ,
Expiration Date ,
Kimble v Marvel Enterprises ,
License Agreements ,
Patent Infringement ,
Patent Royalties ,
Patents ,
SCOTUS ,
Settlement Agreements ,
Stare Decisis ,
Young Lawyers